Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

NCT02311920 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

NIH

Sponsor class

Conditions

Gliosarcoma
Supratentorial Glioblastoma

Interventions

BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab
DRUG: Temozolomide

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]